Affinity Investment Advisors’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.24M Sell
8,898
-37
-0.4% -$7.96K 1.14% 24
2026
Q1
$1.94M Buy
8,935
+6
+0.1% +$1.33K 1.22% 22
2025
Q4
$2.04M Sell
8,929
-68
-0.8% -$15.5K 1.36% 18
2025
Q3
$2.08M Sell
8,997
-154
-2% -$31.4K 1.41% 19
2025
Q2
$1.7M Sell
9,151
-293
-3% -$54.5K 1.29% 21
2025
Q1
$1.98M Sell
9,444
-802
-8% -$156K 1.61% 10
2024
Q4
$1.82M Sell
10,246
-2,222
-18% -$409K 1.52% 15
2024
Q3
$2.46M Sell
12,468
-240
-2% -$44.8K 1.69% 12
2024
Q2
$2.18M Hold
12,708
1.64% 14
2024
Q1
$2.31M Buy
12,708
+1,582
+14% +$273K 1.69% 14
2023
Q4
$1.72M Sell
11,126
-918
-8% -$134K 1.17% 21
2023
Q3
$1.8M Sell
12,044
-344
-3% -$50.5K 1.16% 18
2023
Q2
$1.67M Sell
12,388
-3,622
-23% -$531K 0.97% 28
2023
Q1
$2.55M Sell
16,010
-5,189
-24% -$793K 1.36% 12
2022
Q4
$3.43M Sell
21,199
-1,520
-7% -$233K 1.58% 9
2022
Q3
$3.05M Sell
22,719
-536
-2% -$76.9K 1.58% 8
2022
Q2
$3.56M Sell
23,255
-463
-2% -$70.7K 1.74% 6
2022
Q1
$3.85M Sell
23,718
-2,928
-11% -$425K 1.58% 7
2021
Q4
$3.61M Sell
26,646
-209
-0.8% -$24.7K 1.45% 8
2021
Q3
$2.9M Buy
26,855
+36
+0.1% +$4.11K 1.3% 17
2021
Q2
$3.02M Sell
26,819
-15,950
-37% -$1.8M 1.36% 20
2021
Q1
$4.63M Sell
42,769
-323
-0.7% -$34.5K 1.7% 10
2020
Q4
$4.62M Buy
43,092
+913
+2% +$87.7K 1.86% 7
2020
Q3
$3.69M Buy
42,179
+3,260
+8% +$307K 1.62% 17
2020
Q2
$3.82M Sell
38,919
-290
-0.7% -$25.5K 1.82% 13
2020
Q1
$2.99M Buy
39,209
+13,538
+53% +$1.15M 1.52% 21
2019
Q4
$2.27M Buy
25,671
+2,650
+12% +$220K 0.82% 47
2019
Q3
$1.74M Buy
23,021
+4,202
+22% +$288K 0.55% 58
2019
Q2
$1.37M Buy
18,819
+750
+4% +$59K 0.39% 62
2019
Q1
$1.46M Buy
18,069
+249
+1% +$20.4K 0.3% 64
2018
Q4
$1.64M Sell
17,820
-313
-2% -$27.5K 0.29% 64
2018
Q3
$1.72M Buy
18,133
+9,773
+117% +$927K 0.23% 66
2018
Q2
$775K Sell
8,360
-1,282
-13% -$125K 0.11% 103
2018
Q1
$913K Buy
9,642
+454
+5% +$49.9K 0.11% 100
2017
Q4
$889K Buy
9,188
+140
+2% +$13.2K 0.1% 100
2017
Q3
$804K Sell
9,048
-20
-0.2% -$1.52K 0.09% 104
2017
Q2
$658K Buy
+9,068
New +$610K 0.08% 107
2016
Q2
Sell
-307,219
Closed -$17.5M 161
2016
Q1
$17.5M Buy
307,219
+75,736
+33% +$4.22M 1.54% 21
2015
Q4
$13.7M Sell
231,483
-480
-0.2% -$27.6K 1.18% 38
2015
Q3
$12.6M Buy
231,963
+22,725
+11% +$1.48M 1.15% 40
2015
Q2
$14.1M Sell
209,238
-8,644
-4% -$564K 1.12% 39
2015
Q1
$12.8M Buy
217,882
+62,161
+40% +$3.76M 0.92% 49
2014
Q4
$10.2M Buy
155,721
+8,131
+6% +$513K 0.94% 49
2014
Q3
$8.53M Buy
+147,590
New +$8.19M 0.86% 53

Other funds holding ABBV

Affinity Investment Advisors's ABBV Position: Q2 2026 in Review

Affinity Investment Advisors reduced its AbbVie (ABBV) stake by 0.41% in Q2 2026, selling an estimated $7.96K and leaving 8,898 shares worth $2.24M. The position accounts for 1.14% of the portfolio, ranked #24.

Affinity Investment Advisors first reported a position in ABBV in Q3 2014 and has held it in 44 quarters since. The position peaked at $17.5M in Q1 2016. 4,201 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Affinity Investment Advisors held 8,898 shares of AbbVie worth $2.24M as of Q2 2026.
  • Affinity Investment Advisors sold 37 AbbVie shares in Q2 2026, an estimated $7.96K.
  • AbbVie made up 1.14% of Affinity Investment Advisors's portfolio in Q2 2026, its #24 holding.
  • Affinity Investment Advisors first reported a position in AbbVie in Q3 2014 and has held it in 44 quarters since.
  • Affinity Investment Advisors's AbbVie position peaked at $17.5M in Q1 2016.
  • 4,201 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Affinity Investment Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.